Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows
A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news – an approval of a Phase III clinical test. Will a bright future erase the black stain?
May 22, 2020 10:52 PM
ResearchHealthcare, Consumer Staples, Technology
WIA2020 | Rising Tech Stars 2020: Global & China's 100
Electrophysiology AccuPulse Raises Nearly CNY 100 Million in Series A Funding
Founded in November 2020, Suzhou AccuPulse is committed to becoming an international leading platform-based innovative cardiac electrophysiology company. The company has established a research and development team led by well-known electrophysiological experts in the US with R&D centers in Suzhou and in the United States.
May 20, 2022 05:17 PM
New Normal, New Policies: A Focus on Healthcare in Two Sessions
The week-long Chinese virtual ‘Two Sessions’ meeting closed on May 28. The hovering pandemic has made the healthcare topic a highlight for the 2020 third session of the 13th National People’s Congress.
Jun 03, 2020 03:06 PM